Protalix Q1 net loss $4.6M; PRX-115 phase I positive, adds cohort

Protalix BioTherapeutics, Inc.

2024-Q1 EPS reported -$0.06 revenue$3,748,000

Revenue from goods $3.7M (-27% YoY); license/R&D services $0.1M (-98%) as Elfabrio obligations completed.
Net loss $4.6M ($0.06/shr) vs $3.1M loss ($0.05) YoY; cash $48.5M at quarter end.
PRX-115 phase I: dose-dependent uric acid reduction, well-tolerated; expanding to 8th cohort, planning phase II.
R&D expenses down 50% to $2.9M on completion of Fabry program and Elfabrio regulatory filings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protalix BioTherapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.